The seamless integration of dietary plant-derived natural flavonoids and gut microbiota may ameliorate non-alcoholic fatty liver disease: a network pharmacology analysis
Source abstract
Abstract
We comprised metabolites of gut microbiota (GM; endogenous species) and dietary plant-derived natural flavonoids (DPDNFs; exogenous species) were known as potent effectors against non-alcoholic fatty liver disease (NAFLD) via network pharmacology (NP). The crucial targets against NAFLD were identified via GM and DPDNFs. The protein interaction (PPI), bubble chart and networks of GM or natural products- metabolites-targets-key signalling (GNMTK) pathway were described via R Package. Furthermore, the molecular docking test (MDT) to verify the affinity was performed between metabolite(s) and target(s) on a key signalling pathway. On the networks of GNMTK, Enterococcus sp. 45, Escherichia sp.12, Escherichia sp.33 and Bacterium MRG-PMF-1 as key microbiota; flavonoid-rich products as key natural resources; luteolin and myricetin as key metabolites (or dietary flavonoids); AKT Serine/Threonine Kinase 1 (AKT1), CF Transmembrane conductance Regulator (CFTR) and PhosphoInositide-3-Kinase, Regulatory subunit 1 (PIK3R1) as key targets are promising components to treat NAFLD, by suppressing cyclic Adenosine MonoPhosphate (cAMP) signalling pathway. This study shows that components (microbiota, metabolites, targets and a key signalling pathway) and DPDNFs can exert combinatorial pharmacological effects against NAFLD. Overall, the integrated pharmacological approach sheds light on the relationships between GM and DPDNFs.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Liver Disease Diagnosis and Treatment · Pharmacological Effects of Natural Compounds · Computational Drug Discovery Methods
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
Funding
Hallym University Research Fund · the Basic Science Research Program · National Research Foundation of Korea · the Ministry of Education, Science and Technology
References (68)
Show source-provided references
1. Li B · Can J Gastroenterol Hepatol · 2018 · 2018 · 2784537
2. 10.1038/s41575-020-00381-610.1038/s41575-020-00381-6 ↗
3. 10.1159/00034385210.1159/000343852 ↗
4. Bhandari P · Cureus · 2022 · 14 · 1
5. 10.3390/cancers1317434210.3390/cancers13174342 ↗
6. 10.3389/fimmu.2021.77552610.3389/fimmu.2021.775526 ↗
7. 10.1038/s41423-020-00592-610.1038/s41423-020-00592-6 ↗
8. 10.1093/jn/132.12.357710.1093/jn/132.12.3577 ↗
9. 10.1177/15353702052300030210.1177/153537020523000302 ↗
10. 10.1080/09168451.2018.144446710.1080/09168451.2018.1444467 ↗
11. 10.1017/S000711452100362710.1017/S0007114521003627 ↗
12. 10.3390/molecules2522524310.3390/molecules25225243 ↗
13. 10.1016/j.freeradbiomed.2019.06.01910.1016/j.freeradbiomed.2019.06.019 ↗
14. 10.1007/s13765-016-0150-210.1007/s13765-016-0150-2 ↗
15. 10.1016/j.abb.2021.10901910.1016/j.abb.2021.109019 ↗
16. 10.2174/15680090878624105010.2174/156800908786241050 ↗
17. 10.1016/j.jep.2021.11433610.1016/j.jep.2021.114336 ↗
18. Zhu H · Nutrients · 2022 · 14 · 153310.3390/nu14081533 ↗
19. Li S · Evid Based Complement Alternat Med · 2014 · 2014 · 13846010.1155/2014/138460 ↗
20. 10.1093/nar/gkab78610.1093/nar/gkab786 ↗
21. 10.1038/nbt128410.1038/nbt1284 ↗
22. 10.1093/nar/gkz38210.1093/nar/gkz382 ↗
23. 10.1089/cmb.2019.032310.1089/cmb.2019.0323 ↗
24. 10.1093/nar/gkaa107410.1093/nar/gkaa1074 ↗
25. Raykova D · Nat Commun · 2022 · 13 · 475510.1038/s41467-022-32395-w ↗
26. Guo L · BMC Genomics · 2018 · 19 · 110.1186/s12864-017-4368-0 ↗
27. 10.1007/s13659-020-00260-210.1007/s13659-020-00260-2 ↗
28. 10.1002/0471250953.bi0814s2410.1002/0471250953.bi0814s24 ↗
29. 10.1021/ci200227u10.1021/ci200227u ↗
30. Xu X · J Comput Aided Mol Des · 2017 · 31 · 68910.1007/s10822-017-0038-1 ↗
31. 10.1074/jbc.M116.74313810.1074/jbc.M116.743138 ↗
32. 10.1021/acs.chemrestox.5b0046510.1021/acs.chemrestox.5b00465 ↗
33. 10.1093/toxsci/kfac04210.1093/toxsci/kfac042 ↗
34. 10.1016/j.envint.2019.04.06710.1016/j.envint.2019.04.067 ↗
35. 10.1039/C6RA25267B10.1039/C6RA25267B ↗
36. 10.1016/j.crtox.2021.05.00210.1016/j.crtox.2021.05.002 ↗
37. Dong J · J Cheminform · 2018 · 10 · 1110.1186/s13321-018-0269-8 ↗
38. 10.1016/j.jep.2018.04.02710.1016/j.jep.2018.04.027 ↗
39. Oh KK · J Food Biochem · 2022 · 46 · e14258
40. 10.1021/acs.jmedchem.7b0023710.1021/acs.jmedchem.7b00237 ↗
41. 10.1080/21655979.2022.203737410.1080/21655979.2022.2037374 ↗
42. Hu Q · BioData Min · 2020 · 13 · 1110.1186/s13040-020-00224-9 ↗
43. 10.1016/j.jchromb.2013.11.00210.1016/j.jchromb.2013.11.002 ↗
44. 10.1016/j.jchromb.2015.03.03410.1016/j.jchromb.2015.03.034 ↗
45. 10.1517/17425255.2014.91895410.1517/17425255.2014.918954 ↗
46. Awaad AK · Egyptian Liver Journal · 2020 · 10 · 110.1186/s43066-019-0010-y ↗
47. 10.1016/j.cellsig.2018.06.00510.1016/j.cellsig.2018.06.005 ↗
48. Lu Q · Front Physiol · 2021 · 12 · 71042010.3389/fphys.2021.710420 ↗
49. 10.1111/nyas.1343510.1111/nyas.13435 ↗
50. 10.12944/CRNFSJ.7.2.0910.12944/CRNFSJ.7.2.09 ↗
51. 10.1016/j.jff.2013.06.00410.1016/j.jff.2013.06.004 ↗
52. Jeong SH · BMB Rep · 2018 · 51 · 20910.5483/BMBRep.2018.51.5.095 ↗
53. 10.4254/wjh.v10.i1.3410.4254/wjh.v10.i1.34 ↗
54. Zhang W · J Physiol Biochem · 2017 · 73 · 58310.1007/s13105-017-0589-6 ↗
55. 10.3350/cmh.2020.013710.3350/cmh.2020.0137 ↗
56. Brandt A · Sci Rep · 2019 · 9 · 110.1038/s41598-018-37186-2 ↗
57. Li L · Mol Med Rep · 2018 · 17 · 7708
58. 10.1007/s00335-014-9521-310.1007/s00335-014-9521-3 ↗
59. Hashida R · Life · 2021 · 11 · 79910.3390/life11080799 ↗
60. Yang X · Int J Biol Sci · 2020 · 16 · 235710.7150/ijbs.46405 ↗
61. 10.1016/j.phymed.2021.15349810.1016/j.phymed.2021.153498 ↗
62. Pan X · Front Immunol · 2020 · 11 · 180210.3389/fimmu.2020.01802 ↗
63. Luo D · IScience · 2021 · 24 · 10212510.1016/j.isci.2021.102125 ↗
64. 10.1007/s00726-017-2429-y10.1007/s00726-017-2429-y ↗
65. 10.1002/hep.2667210.1002/hep.26672 ↗
66. 10.3748/wjg.v21.i13.377710.3748/wjg.v21.i13.3777 ↗
67. Zhang Y · BMC Endocr Disord · 2022 · 22 · 110.1186/s12902-021-00919-y ↗
68. Oh K-K, Gupta H, Ganesan R, et al. A network pharmacology study to determine the integrated application of dietary plant-derived natural flavonoids and gut microbiota against nonalcoholic fatty liver disease. 2022; https://doi.org/10.21203/rs.3.rs-1996432/v110.21203/rs.3.rs-1996432/v1 ↗